Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010470 | 0.97 | SIRT2 (0.39) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL10310593 | 0.90 | SIRT2 (0.41) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL10066896 | 0.88 | CPB1 (0.32) | SIRT2SIRT1CPB1CPB2SIRT5 | |
| SCHEMBL14753623 | 0.84 | SIRT2 (0.38) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL13367216 | 0.81 | SIRT5 (0.33) | SIRT2SIRT1CPB1CPB2SIRT5 | |
| SCHEMBL11955643 | 0.80 | SIRT2 (0.43) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL327667 | 0.80 | SIRT1 (0.36) | SIRT2SIRT1CPB1CPB2SIRT3 | |
| SCHEMBL13531987 | 0.79 | SIRT2 (0.41) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL18470788 | 0.79 | SIRT2 (0.37) | SIRT2SIRT1HDAC4EP300MEF2D | |
| SCHEMBL12497446 | 0.78 | CPB1 (0.36) | SIRT2SIRT1CPB1CPB2SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NEKTAR THERAPEUTICS (US) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NGLY1, DNPEP, CIAPIN1 | SIRT2 4454/4885SIRT1 4002/4885HDAC4 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.